CN117083279A - 氧氮杂䓬化合物及其在癌症治疗中的用途 - Google Patents

氧氮杂䓬化合物及其在癌症治疗中的用途 Download PDF

Info

Publication number
CN117083279A
CN117083279A CN202280026974.XA CN202280026974A CN117083279A CN 117083279 A CN117083279 A CN 117083279A CN 202280026974 A CN202280026974 A CN 202280026974A CN 117083279 A CN117083279 A CN 117083279A
Authority
CN
China
Prior art keywords
unsubstituted
substituted
compound
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280026974.XA
Other languages
English (en)
Chinese (zh)
Inventor
L·J·加扎德
S·A·格伦
E·H·凯利
M·L·兰德里
S·马尔霍特拉
B·D·拉维茨
M·休
J·A·特雷特
魏斌清
S·多
程云行
程丽敏
信建峰
何明桃
吴国胜
孙银蕾
邵成
陆爱军
张玉来
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN117083279A publication Critical patent/CN117083279A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202280026974.XA 2021-04-08 2022-04-06 氧氮杂䓬化合物及其在癌症治疗中的用途 Pending CN117083279A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021085959 2021-04-08
CNPCT/CN2021/085959 2021-04-08
PCT/US2022/023573 WO2022216762A1 (en) 2021-04-08 2022-04-06 Oxazepine compounds and uses thereof in the treatment of cancer

Publications (1)

Publication Number Publication Date
CN117083279A true CN117083279A (zh) 2023-11-17

Family

ID=81387302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280026974.XA Pending CN117083279A (zh) 2021-04-08 2022-04-06 氧氮杂䓬化合物及其在癌症治疗中的用途

Country Status (12)

Country Link
US (1) US20240383915A1 (https=)
EP (1) EP4320132A1 (https=)
JP (1) JP2024513881A (https=)
KR (1) KR20230167386A (https=)
CN (1) CN117083279A (https=)
AR (1) AR125304A1 (https=)
AU (1) AU2022254674A1 (https=)
BR (1) BR112023020773A2 (https=)
CA (1) CA3215949A1 (https=)
MX (1) MX2023011873A (https=)
TW (1) TWI868441B (https=)
WO (1) WO2022216762A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025168072A1 (en) * 2024-02-08 2025-08-14 Beigene (Suzhou) Co., Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2025167948A1 (zh) * 2024-02-06 2025-08-14 上海齐鲁制药研究中心有限公司 嘧啶并大环类kras抑制剂

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
KR20240163107A (ko) 2022-03-11 2024-11-18 컴쿼트 바이오사이언시즈 인크. 헤테로환 화합물 및 이의 용도
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CA3261681A1 (en) 2022-08-05 2024-02-08 Kumquat Biosciences Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
AU2023320914A1 (en) * 2022-08-11 2025-02-27 Beone Medicines I Gmbh Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024041573A1 (en) * 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
JP2025535294A (ja) * 2022-10-18 2025-10-24 アイディーエンス カンパニー リミテッド 新規なトリヘテロ環化合物
JP2025535367A (ja) * 2022-10-19 2025-10-24 ジェネンテック， インコーポレイテッド ６－アザ部分を含むオキサゼピン化合物およびその使用
WO2024112654A1 (en) 2022-11-21 2024-05-30 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
WO2024153180A1 (zh) * 2023-01-18 2024-07-25 上海艾力斯医药科技股份有限公司 杂环类化合物、其药物组合物及其用途
CN121419983A (zh) 2023-01-26 2026-01-27 阿尔维纳斯运营股份有限公司 基于小脑蛋白的kras降解protac及其相关用途
WO2024197503A1 (en) * 2023-03-27 2024-10-03 Nikang Therapeutics , Inc. Tricyclic derivatives as kras inhibitors
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
EP4713330A1 (en) * 2023-05-16 2026-03-25 HUTCHMED Limited Tricyclic compounds and uses thereof
CN121605110A (zh) * 2023-06-06 2026-03-03 金橘生物科技公司 取代杂环化合物及其用途
AU2024307234A1 (en) * 2023-06-30 2026-01-29 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
CN116903499B (zh) * 2023-07-11 2025-05-30 上海应用技术大学 无水氟磺酰基二氟乙酸铜盐及其制备方法与应用
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
AU2024323424A1 (en) 2023-08-17 2026-03-05 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
TW202528315A (zh) 2023-09-21 2025-07-16 美商樹線生物科學公司 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
US20250163079A1 (en) * 2023-11-01 2025-05-22 Incyte Corporation Kras inhibitors
WO2025111586A1 (en) 2023-11-22 2025-05-30 Genentech, Inc. Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d
TW202527946A (zh) * 2023-12-19 2025-07-16 大陸商正大天晴藥業集團股份有限公司 三并環類化合物及其醫藥用途
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
WO2019215203A1 (en) * 2018-05-08 2019-11-14 Astrazeneca Ab Tetracyclic heteroaryl compounds
WO2020178282A1 (en) * 2019-03-05 2020-09-10 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
CN112574224A (zh) * 2019-09-30 2021-03-30 上海迪诺医药科技有限公司 Kras g12c抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CR20190157A (es) * 2016-08-31 2019-08-13 Agios Pharmaceuticals Inc Inhibidores de procesos metabólicos celulares

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
WO2019215203A1 (en) * 2018-05-08 2019-11-14 Astrazeneca Ab Tetracyclic heteroaryl compounds
WO2020178282A1 (en) * 2019-03-05 2020-09-10 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
CN112574224A (zh) * 2019-09-30 2021-03-30 上海迪诺医药科技有限公司 Kras g12c抑制剂及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025167948A1 (zh) * 2024-02-06 2025-08-14 上海齐鲁制药研究中心有限公司 嘧啶并大环类kras抑制剂
WO2025168072A1 (en) * 2024-02-08 2025-08-14 Beigene (Suzhou) Co., Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
TW202304934A (zh) 2023-02-01
JP2024513881A (ja) 2024-03-27
AU2022254674A1 (en) 2023-10-12
AR125304A1 (es) 2023-07-05
KR20230167386A (ko) 2023-12-08
US20240383915A1 (en) 2024-11-21
MX2023011873A (es) 2023-10-17
CA3215949A1 (en) 2022-10-13
WO2022216762A1 (en) 2022-10-13
TWI868441B (zh) 2025-01-01
BR112023020773A2 (pt) 2024-01-30
EP4320132A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
TWI868441B (zh) 非環氧氮呯化合物及其用途
TWI824405B (zh) 四環氧氮呯化合物及其用途
US12338256B2 (en) Aza-tetracyclic oxazepine compounds and uses thereof
JP7374960B2 (ja) 縮合環化合物
CN112119075B (zh) 稠环化合物
CN120092009A (zh) 包含6-氮杂部分的氧氮杂䓬化合物及其用途
HK40099028A (zh) 氧氮杂䓬化合物及其在癌症治疗中的用途
WO2025194134A1 (en) Linearly substituted oxazepin-5-one kras-g12d inhibitors
HK40041215A (en) Fused ring compounds
HK40040938A (en) Fused ring compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40099028

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination